Abstract:Abstract Background Anti-synthetase syndrome (ASSD) is a chronic autoimmune condition characterized by antibodies directed against an aminoacycl transfer RNA synthetase (ARS) along with a group of clinical features including the classical clinical triad: inflammatory myopathy, arthritis, and interstitial lung disease (ILD). ASSD is highly heterogenous due to different organ involvement, and ILD is the main cause of mortality and function loss, which presents as different patterns when diagnosed. We designed this retrospective cohort to describe the clinical features and disease behaviour of ASSD associated ILD. Methods Data of 108 cases of ASSD associated ILD were retrospectively collected in Beijing Chaoyang Hospital from December 2017 to March 2019. Data were obtained from the Electronic Medical Record system. Patients were divided into 5 groups according to distinct aminoacyl tRNA synthetase (ARS) antibodies. Results Overall, 108 consecutive patients were recruited. 33 were JO-1 positive, 30 were PL-7 positive, 23 were EJ positive, 13 were PL-12 positive and 9 were OJ positive. The JO-1 (+) group had a significant higher rate of mechanic’s hand (57.6%) than other 4 groups. Polymyositis/dermatomyositis (PM/DM) was diagnosed in 25 (23.1%) patients and no difference was observed among the 5 groups. The PL-7 (+) group had a higher frequency of UIP pattern (13.3%) than the other 4 groups but the difference was not significant, and the EJ (+) group had the most frequent OP pattern (78.2%), which was significantly higher than the PL-7 (+) (P < 0.001) and PL-12 (+) groups (P = 0.025). The median follow-up time was 10.7 months, during which no patients died. All received prednisone treatment, with or without immunosuppressants. At the 6-month follow-up, 96.3% of all patients (104/108) had a positive response to therapy, the JO-1 (+) and EJ (+) groups had a significantly higher improvement of forced vital capacity than the other 3 groups (P < 0.05), and the PL-7 group had the lowest FVC improvement (P < 0.05). The JO-1 (+) group and EJ (+) group had significantly higher anti-Ro-52 positive occurrence than the other 3 groups (P < 0.05). Conclusion Anti PL-7 antibody had the same frequency as anti-JO-1 in ASSD-ILD, in which the ILD pattern was different with distinct anti-ARS antibodies. Most ASSD-ILD had a positive response to steroid therapies, with or without immunosuppressants. The PL-7 (+) group had the highest occurrence of UIP pattern, and a significantly lower response to therapy.

A narrative review of interstitial lung disease in anti-synthetase syndrome: a clinical approach

A Review of Antisynthetase Syndrome-Associated Interstitial Lung Disease

Review of Pulmonary Manifestations in Antisynthetase Syndrome

A novel take on idiopathic pulmonary fibrosis disease progression: localised autoimmunity

Interleukin 6 inhibition in refractory antisynthetase syndrome: case-based literature review

Clinical features of anti-synthetase syndrome associated interstitial lung disease: a retrospective cohort in China

Screening, diagnosis, and monitoring of interstitial lung disease in autoimmune rheumatic diseases: A narrative review

Clinical characteristics of patients with anti-EJ antisynthetase syndrome associated interstitial lung disease and literature review

A Practical Multidisciplinary Approach to Identifying Interstitial Lung Disease in Systemic Autoimmune Rheumatic Diseases: A Clinician's Narrative Review

Immune-mediated lung diseases: A narrative review

Clinical Features, Prognostic Factors, and Survival of Patients with Antisynthetase Syndrome and Interstitial Lung Disease.

Antisynthetase Syndrome: A Distinct Disease Spectrum

[Treatment Strategies for Anti-Synthetase Syndrome].

Natural history of indolent-anti-synthetase syndrome-associated interstitial lung disease

Anti-PL-12 anti-synthetase syndrome manifesting with multiple digital ischemia: Case report & review of the literature

Myositis-Associated Interstitial Lung Disease: The Experience of a Tertiary Center

Clinical characteristics of interstitial lung diseases positive to different anti-synthetase antibodies

Role of autoantibodies in the diagnosis and prognosis of interstitial lung disease in autoimmune rheumatic disorders

Diagnostic Approach to Interstitial Lung Diseases Associated with Connective Tissue Diseases

Detection and Monitoring of Interstitial Lung Disease in Patients with Systemic Sclerosis

Interstitial lung disease in Systemic sclerosis: insights into pathogenesis and evolving therapies